

Amgen's Oncology Clinical Trials

AMGEN

GASTRIC/GASTROESOPHAGEAL JUNCTION CANCER



Bemarituzumab
Monoclonal antibody targeting FGFR2b

NCT / Amgen ID*		Status	Phase
NCT: 05052801 Amgen ID*: 20210096	**FORTITUDE-101:** A Phase 3 Study of Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression	Ⓡ	3
NCT: 05111626 Amgen ID*: 20210098	**FORTITUDE-102:** A Phase 1b/3 Study of Bemarituzumab plus Chemotherapy and Nivolumab versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric/ Gastroesophageal Junction Cancer With FGFR2b Overexpression	Ⓡ	1b/3
NCT: 05322577 Amgen ID*: 20210099	**FORTITUDE-103:** A Phase 1b Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression	Ⓡ	1b

GASTROINTESTINAL, PANCREATIC, OR COLORECTAL CANCER



Romiplostim
Protein/peptibody (thrombopoiesis stimulator)

NCT / Amgen ID*		Status	Phase
NCT: 03362177 Amgen ID*: 20140346	Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Gastrointestinal, Pancreatic, or Colorectal Cancer	Ⓐ	3



Sotorasib + Panitumumab
Small molecule targeting KRAS ^{G12C} + Monoclonal antibody targeting EGFR

NCT / Amgen ID*		Status	Phase
NCT: 05198934 Amgen ID*: 20190172	**CodeBreaK 300:** A Phase 3 Multicenter, Randomized, Open-Label, Active-Controlled Study of Sotorasib and Panitumumab Versus Investigator's Choice (Trifluridine with Tipiracil, or Regorafenib) for the Treatment of Previously Treated Metastatic Colorectal Subjects with *KRAS* G12C Mutation	Ⓐ	3

Ⓟ Potentially may resume Ⓝ Not yet recruiting Ⓡ Active, recruiting Ⓐ Active, not recruiting Ⓒ Completed, pending results Ⓩ Completed, with results

LUNG CANCER NON-SMALL CELL LUNG CANCER



AMG 193
MTA-cooperative PRMT5 inhibitor

NCT / Amgen ID*		Status	Phase
NCT: 05094336 Amgen ID*: 20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-Null Solid Tumors	Ⓡ	1/1b/2
NCT: 05975073 Amgen ID*: 20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	Ⓡ	1/2



AMG 794
BiTE® molecule targeting CLDN6

NCT / Amgen ID*		Status	Phase
NCT: 05317078 Amgen ID*: 20210007	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6-positive Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer	Ⓡ	1



Sotorasib
Small molecule (KRAS ^{G12C} inhibitor)

NCT / Amgen ID*		Status	Phase
NCT: 03600883 Amgen ID*: 20170543	**CodeBreaK 100**: Open-Label Study Evaluating Sotorasib Monotherapy in Advanced Solid Tumors and in Combination Therapy With Anti-PD-1/L1 in NSCLC With *KRAS* G12C Mutation	Ⓐ	1/2
NCT: 04185883 Amgen ID*: 20190135	**CodeBreaK 101**: Open-Label Study Evaluating Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With *KRAS* G12C Mutation	Ⓡ	1b/2
NCT: 04380753 Amgen ID*: 20190147	**CodeBreaK 105**: Open-Label Study Evaluating Sotorasib Monotherapy in Patients of Chinese Descent With Advanced Solid Tumors With *KRAS* G12C Mutation	Ⓐ	1
NCT: 04303780 Amgen ID*: 20190009	**CodeBreaK 200**: A Phase 3 Study to Compare Sotorasib With Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC With *KRAS* G12C Mutation	Ⓐ	3
NCT: 04933695 Amgen ID*: 20190288	**CodeBreaK 201**: Open Label Study of Sotorasib in Untreated Patients with Stage IV *KRAS* G12C-mutated NSCLC with PD-L1 <1% and/or *STK11* Mutation	Ⓐ	2
NCT: 05920356 Amgen ID*: 20190341	**CodeBreaK 202**: Phase 3 Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as Front-Line Therapy in Advanced/Metastatic PD-L1-Negative NSCLC with *KRAS* G12C Mutation	Ⓝ	3

LUNG CANCER SMALL CELL LUNG CANCER



Tarlatamab
BiTE® molecule targeting DLL3

NCT	Amgen ID*	Study	Status	Phase
03319940	20160323	**DeLLphi-300:** First-in-Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Tarlatamab in SCLC	R	1
05060016	20200491	**DeLLphi-301:** A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in 2L+ Relapsed/Refractory SCLC	A	2
05361395	20200469	**DeLLphi-303:** A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination with Carboplatin, Etoposide, and PD-L1 Inhibitor in Extensive Stage SCLC	R	1b
05740566	20210004	**DeLLphi-304:** A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy	R	3

PROSTATE CANCER



Xaluritaming (AMG 509)
XmAb® 2+1 T-cell engager targeting STEAP1

NCT	Amgen ID*	Study	Status	Phase
04221542	20180146	Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer	R	1



Tarlatamab
BiTE® molecule targeting DLL3

NCT	Amgen ID*	Study	Status	Phase
04702737	20200040	**DeLLpro-300:** Study Evaluating Tarlatamab in Patients With De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer	A	1b

VARIOUS SOLID TUMORS

ABP 206
Monoclonal antibody (nivolumab biosimilar)

NCT	Amgen ID*	Study	Status	Phase
05907122	20220083	A Study to Evaluate Pharmacokinetic Similarity of ABP 206 Compared With Nivolumab in Subjects With Resected Stage III or IV Melanoma	R	3



AMG 193
MTA-cooperative PRMT5 inhibitor

NCT	Amgen ID*	Study	Status	Phase
05094336	20210023	A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-Null Solid Tumors	R	1
05975073	20220127	A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors	R	1/2



AMG 256
Bi-functional fusion protein (Targeted IL-21 receptor agonist)

NCT	Amgen ID*	Study	Status	Phase
04362748	20180144	A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 256 in Patients With Advanced Solid Tumors	C	1

AMG 305
Dual-targeting bispecific T cell engager (BiTE) molecule

NCT	Amgen ID*	Study	Status	Phase
05800964	20220073	Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors.	R	1

AMG 794
BiTE® molecule targeting CLDN6

NCT	Amgen ID*	Study	Status	Phase
05317078	20210007	Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Subjects With Claudin 6-positive Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer.	R	1

P Potentially may resume · N Not yet recruiting · R Active, recruiting · A Active, not recruiting · C Completed, pending results · Z Completed, with results

Bemarituzumab
Monoclonal antibody targeting FGFR2b

NCT / Amgen ID*	Status	Phase
NCT: 05325866 Amgen ID*: 20210104 **FORTITUDE-301:** A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression	Ⓡ	1b/2



Romiplostim
Protein/peptibody (thrombopoiesis stimulator)

NCT / Amgen ID*	Status	Phase
NCT: 03937154 Amgen ID*: 20170770 Study of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients With Non-small Cell Lung, Ovarian, or Breast Cancer	Ⓡ	3



Sotorasib
Small molecule (KRAS ^{G12C} inhibitor)

NCT / Amgen ID*	Status	Phase
NCT: 03600883 Amgen ID*: 20170543 **CodeBreaK 100:** Open-Label Study Evaluating Sotorasib Monotherapy in Advanced Solid Tumors With *KRAS* G12C Mutation	Ⓐ	1/2
NCT: 04185883 Amgen ID*: 20190135 **CodeBreaK 101:** Open-Label Study Evaluating Sotorasib Monotherapy and in Combination With Other Anti-Cancer Therapies in Advanced Solid Tumors With *KRAS* G12C Mutation	Ⓡ	1b/2
NCT: 04380753 Amgen ID*: 20190147 **CodeBreaK 105:** Open-Label Study Evaluating Sotorasib Monotherapy in Patients of Chinese Descent With Advanced Solid Tumors With *KRAS* G12C Mutation	Ⓐ	1

LEUKEMIA



AMG 176
Small molecule (MCL-1 inhibitor)

NCT / Amgen ID*	Status	Phase
NCT: 02675452 Amgen ID*: 20150161 AMG 176 First in Human Trial in Participants with Relapsed or Refractory Multiple Myeloma and Participants with Relapsed or Refractory Acute Myeloid Leukemia	Ⓡ	1
NCT: 05209152 Amgen ID*: 20200392 AMG 176 with Azacitidine in subjects with Higher-Risk Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia	Ⓡ	1



Blinatumomab
BiTE® molecule targeting CD19

NCT / Amgen ID*	Status	Phase
NCT: 04506086 Amgen ID*: 20190014 Study of Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor ALL	Ⓡ	4
NCT: 04994717 Amgen ID*: 20190360 **Golden Gate Study:** Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-precursor ALL	Ⓡ	3
NCT: 04521231 Amgen ID*: 20180257 Study of Subcutaneous Blinatumomab Administration in ALL	Ⓡ	1/2



Carfilzomib‡
Small molecule (proteasome inhibitor)

NCT / Amgen ID*	Status	Phase
NCT: 02303821 Amgen ID*: 20140106 Study of the Safety, Tolerability, and Activity of Carfilzomib, Alone and in Combination With Induction Chemotherapy, in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia	Ⓡ	1b/2

Ⓟ Potentially may resume Ⓝ Not yet recruiting Ⓡ Active, recruiting Ⓐ Active, not recruiting Ⓒ Completed, pending results Ⓩ Completed, with results

MULTIPLE MYELOMA



Carfilzomib‡
Small molecule (proteasome inhibitor)

NCT: 03859427	Amgen ID*: 20180015	Status	
Study of Once-Weekly vs Twice-Weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma (A.R.R.O.W.2)		C	Phase 3

NCT: 04191616	Amgen ID*: 20180117	Status	
Study of Carfilzomib Plus Pomalidomide and Dexamethasone in Patients With First or Second Relapse of Multiple Myeloma (SELECT)		A	Phase 2

OTHER PAROXYSMAL NOCTURNAL HEMOGLOBINURIA



ABP 959§
Monoclonal antibody (eculizumab biosimilar)

NCT: 03818607	Amgen ID*: 20150168	Status	
Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)		Z	*Clinical Comparability*

*For more detailed information about the trial, visit www.clinicaltrials.gov or www.amgenpipeline.com. †Previously referred to as OncoVEXGM-CSF. XmAb® is a registered trademark of Xencor. ‡Sponsored by Onyx Pharmaceuticals, an Amgen subsidiary. §The regulatory approval pathway for biosimilars requires study of a single indication and permits extrapolation to other reference indications with scientific justification.

ALL – acute lymphoblastic leukemia; **BiTE®** – bispecific T-cell engager; **CAR** = Chimeric Antigen Receptor; **CD** – cluster of differentiation; **CLDN6** - claudin-6 protein; **CLDN18.2** – claudin-18 isoform 2; **DARPin®** – designed ankyrin repeat proteins; **DLL3** – delta-like ligand 3; **EGFR** – epidermal growth factor receptor; **EGFRvIII** – epidermal growth factor receptor variant III; **FGFR2b** – fibroblast growth factor receptor 2b; **IL-21** – interleukin-21; **IV** – intravenous; ***KRAS*** – Kirsten rat sarcoma viral oncogene homolog; **mAb** – monoclonal antibody; **mCRPC** – metastatic castration-resistant prostate cancer; **MCL-1** – myeloid cell leukemia sequence 1; **MM** – multiple myeloma; **MRD** – minimal residual disease; **MTA** – methylthioadenosine; **MTAP** – methylthioadenosine phosphorylase; **NSCLC** – non-small cell lung cancer; **PD-1** – programmed cell death protein-1; **PNH** – paroxysmal nocturnal hemoglobinuria; **PRMT5** – protein arginine methyltransferase 5; **PSMA** – prostate-specific membrane antigen; **RR** – relapsed or refractory. **SCLC** – small cell lung cancer; **STK11** – serine/threonine kinase 11; **STEAP1** – six-transmembrane epithelial antigen of the prostate; **T-VEC** – talimogene laherparepvec; **3L+** – third-line or later treatments.

Information as of October 10, 2023. Statements are based on the company's current beliefs and Amgen disclaims any duty to update. For more information about Amgen and its business, including risks and uncertainties, please refer to Amgen's filings with the SEC. Products under investigational study have not been approved by regulatory agencies for the use under investigation. This information is provided only for purposes of providing general information on clinical trials and stages of development on the select candidates identified. This information should not be construed as a recommendation for use of any product for unapproved uses.

MULTISPECIFICS AND OTHER MODALITIES

Bi-functional Fusion Protein



BiTE® Molecules



Monoclonal Antibody



Peptibody



Small Molecule



CAR T Cell



XmAb® 2+1 T-cell Engager



Oncolytic Viral Therapy



Disclaimer: Amgen's product pipeline will change over time as molecules move through the drug development process, including progressing to market or failing in clinical trials, due to the nature of the development process.

BiTE® = bispecific T-cell engager; **CAR** = chimeric antigen receptor; **XmAb®** is a registered trademark of Xencor.

AMGEN'S RESEARCH AND DEVELOPMENT STRATEGY

OUR VISION

A world where science defeats all disease.

OUR PRIORITIES

Improve our success rates. Focus our people and investments more intensely on the most promising technologies and activities most likely to lead to new therapies.

Reduce cycle times. The industry's standard timeline of 12 to 14 years from project start to drug approval is not viable. Amgen has already reduced its drug development timelines, but there is still ample room for improvements.

Broaden access and use. Gaining regulatory approval for new therapies is only half the battle. In the end, only one metric matters: Are the patients who need Amgen medicines actually getting them?

OUR STRATEGIC IMPERATIVES

Make focused investment in innovative research platforms

- Focus research investments in cardiovascular and metabolic, inflammation and cancer therapeutic areas. Rapidly expand the scale and diversity of our human omics platforms to move towards a precision medicine approach to drug discovery and development.
- Expand our human data resources to include proteomics, transcriptomics and clinical/real world data. This will generate deeper insights into disease biology, find new drug targets and speed up clinical trials.
- Use our molecular engineering strength combined with the power of AI/machine learning to expand on the success of current drug platforms, including multispecifics such as BiTE® molecules, and pioneer novel modalities to address targets now seen as undruggable.

Innovate in Clinical Development

- Increase the speed and efficiency of clinical trials and improve success rates through greater use of modelling and simulation, adaptive designs and real-world evidence.
- Increase recruitment of patients who will potentially benefit most from new therapies, design smaller and faster studies with larger response rates by using human data, including genetics and omics.

Address access and use at all stages of drug development

- Engage with healthcare professionals, regulators and payors to enable broader and faster access to therapies.
- Accelerate bringing molecules from the lab, through the clinic, to approval and to patients around the world because of the immense interconnected R&D ecosystem so the patients who need our medicines most are getting them as fast as possible.

SUPPORT OUR PEOPLE

- Our past and future success relies on our people – they form the foundation for all that we do. We will continue to build an R&D culture that supports, develops and nurtures a diverse talent base energized by the rapid scientific progress and new technology we are using to push the boundaries of science. Our teams are vested in a collective accountability for our success.

AMGEN